How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies

In the last five years, everolimus has demonstrated efficacy in the treatment of neuroendocrine tumors (NETs) of different origins; its efficacy and safety were explored in the RADIANT trials, the last of which (RADIANT-4) has been recently published (December 2015). Overall, evidence collected from...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncotarget 2016-07, Vol.7 (28), p.44841-44847
Hauptverfasser:	Pusceddu, Sara, De Braud, Filippo, Lo Russo, Giuseppe, Concas, Laura, Femia, Daniela, Vernieri, Claudio, Indini, Alice, Formisano, Barbara, Buzzoni, Roberto
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Everolimus - administration & dosage Everolimus - therapeutic use Humans Neuroendocrine Tumors - drug therapy Octreotide - administration & dosage Outcome Assessment (Health Care) - methods Outcome Assessment (Health Care) - statistics & numerical data Randomized Controlled Trials as Topic Review Survival Analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In the last five years, everolimus has demonstrated efficacy in the treatment of neuroendocrine tumors (NETs) of different origins; its efficacy and safety were explored in the RADIANT trials, the last of which (RADIANT-4) has been recently published (December 2015). Overall, evidence collected from the RADIANT studies holds promise to change clinical practice for the treatment of NETs.In this paper, we comment on the role of everolimus within the therapeutic algorithm for NETs treatment, based on the systematic analysis of the RADIANT trials and our experience.
ISSN:	1949-2553 1949-2553
DOI:	10.18632/oncotarget.8601